Potential use of nanoparticle based contrast agents in MRI: A molecular imaging perspective

Journal of Biomedical Nanotechnology

Volumn 6, Issue 3, 2010, Pages 203-213

  Oghabian, Mohammad A ^a,b   Farahbakhsh, Nima M ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Gadolinium contrast agents; Magnetic nanoparticles; Molecular biomarkers; Molecular imaging; Molecular MRI; Molecular targeting; Superparamagnetic iron oxide nanoparticles

Indexed keywords

CONTRAST AGENT; MAGNETIC NANOPARTICLES; MOLECULAR BIOMARKER; MOLECULAR TARGETING; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLES;

CHEMICAL DETECTION; DRUG DELIVERY; GADOLINIUM; NANOPARTICLES; SUPERPARAMAGNETISM; TISSUE;

MOLECULAR IMAGING;

CONTRAST MEDIUM; IRON OXIDE; MAGNETIC NANOPARTICLE; NANOPARTICLE; DIAGNOSTIC AGENT;

ANGIOGENESIS; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR SYSTEM; COMPUTER ASSISTED TOMOGRAPHY; ENZYME ACTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HALF LIFE TIME; HUMAN; INFLAMMATION; INTERMETHOD COMPARISON; LIVER; LYMPH NODE; MOLECULAR IMAGING; NEOPLASM; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIATION PHYSICS; RADIOFREQUENCY; RETICULOENDOTHELIAL SYSTEM; REVIEW; IMAGE ENHANCEMENT; METHODOLOGY;

CONTRAST MEDIA; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NANOPARTICLES;

EID: 79952196971     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2010.1119     Document Type: Review

References (85)

1. G. M. Lanza, D. R. Abendschein, X. Yu, P. M. Winter, K. K. Karukstis, M. J. Scott, R. W. Fuhrhop, D. E. Scherrer, and S. A. Wickline, Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. Acad. Radiol. 9, 330 (2002).
2. J. C. Frias, K. J. Williams, E. A. Fisher, and Z. A. Fayad, Recombinant HDL-like nanoparticles: A specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126, 16316 (2004).
3. M. J. Lipinski, V. Amirbekian, J. C. Frias, J. G. Aguinaldo, V. Mani, K. C. Briley-Saebo, V. Fuster, J. T. Fallon, E. A. Fisher, and Z. A. Fayad, MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn. Reson. Med. 56, 601 (2006).
4. T. Shen, R. Weissleder, M. Papisov, A. Bogdanov, and T. J. Brady, Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magn. Reson. Med. 29, 599 (1993).
5. P. Wunderbaldinger, L. Josephson, and R. Weissleder, Crosslinked iron oxides (CLIO): A new platform for the development of targeted MR contrast agents. Acad. Radiol. 9, 304 (2002).
6. J. R. Alger and T. F. Cloughesy, Structural and functional imaging of cerebral neoplasia. Academic Press 11, 387 (2000).
7. S. Cha, G. Johnson, Y. Z. Wadghiri, O. Jin, J. Babb, D. Zagzag, and D. H. Turnbul, Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: Correlation with histopathology. Magn. Reson. Med. 49, 848 (2003).
8. L. Ostergaard, A. G. Sorensen, K. K. Kwong, R. M. Weisskoff, C. Gyldensted, and B. R. Rosen, High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part II: Experimental comparison and preliminary results. Magn. Reson. Med. 36, 726 (1996).
9. L. Ostergaard, R. M. Weisskoff, D. A. Chesler, C. Gyldensted, and B. R. Rosen, High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn. Reson. Med. 36, 715 (1996).
10. S. E. Turvey, E. Swart, M. C. Denis, U. Mahmood, C. Benoist, R. Weissleder, and D. Mathis, Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J. Clin. Invest. 115, 2454 (2005).
11. D. L. Kraitchman, A. W. Heldman, E. Atalar, L. C. Amado, B. J. Martin, M. F. Pittenger, J. M. Hare, and J. W. Bulte, In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 107, 2290 (2003).
12. M. Lewin, N. Carlesso, C. H. Tung, X. W. Tang, D. Cory, D. T. Scadden, and R. Weissleder, Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotechnol. 18, 410 (2000).
13. R. M. Botnar, A. Buecker, A. J. Wiethoff, E. C. Parsons, M. Katoh, G. Katsimaglis, R. M. Weisskoff, R. B. Lauffer, P. B. Graham, R. W. Gunther, W. J. Manning, and E. Spuentrup, In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 110, 1463 (2004).
14. R. Weissleder, D. D. Stark, B. L. Engelstad, B. R. Bacon, C. C. Compton, D. L. White, P. Jacobs, and J. Lewis, Superparamagnetic iron oxide: Pharmacokinetics and toxicity. Am. J. Roentgenol. 152, 167 (1989).
15. P. Wunderbaldinger, L. Josephson, and R. Weissleder, Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug. Chem. 13, 264 (2002).
16. F. A. Jaffer, M. Nahrendorf, D. Sosnovik, K. A. Kelly, E. Aikawa, and R. Weissleder, Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 5, 85 (2006).
17. R. M. Botnar, A. S. Perez, S. Witte, A. J. Wiethoff, J. Uredo, J. Hamilton, W. Quist, E. Parsons, A. Vaidya, A. kolodziej, J. Barrett, P. Graham, R. Weisskoff, W. Manning, and M. T. Johnstone, In vivo molecular imaging of acute and subacute thrombosisusing a fibrin-binding magnetic resonance imaging contrast agent. Circulation 109, 2023 (2004).
18. P. Caravan, B. Das, S. Dumas, F. H. Epstein, P. A. Helm, V. Jaques, S. Koerner, A. Kolodziej, L. Shen, W. C. Sun, and Z. Zhang, Collagen-targeted MRI contrast agent for molecular imaging of fibrosis. Chem. Int. Ed. Engl. 46, 8171 (2007).
19. J. C. Frias, K. J. Williams, E. A. Fisher, and Z. A. Fayad, Recombinant HDL-like nanoparticles: A specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126, 16316 (2004).
20. P. M. Winter, A. M. Neubauer, S. D. Caruthers, T. D. Harris, J. D. Robertson, T. A. Williams, A. H. Schmieder, G. Hu, J. S. Allen, E. K. Lacy, H. Zhang, S. A. Wickline, and G. M. Lanza, Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb. Vasc. Biol. 26, 2103 (2006).
21. J. C. Frias, Y. Ma, K. J. Williams, Z. A. Fayad, and E. A. Fisher, Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 6, 2220 (2006).
22. V. Amirbekian, M. J. Lipinski, K. C. Briley-Saebo, S. Amirbekian, J. Aguinaldo, D. B. Weinreb, E. Vucic, J. C. Frias, F. Hyafil, V. Mani, E. A. Fisher, and Z. A. Fayad, Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc. Natl. Acad. Sci. 104, 961 (2007).
23. T. Shen, R. Weissleder, M. Papisov, A. Bogdanov, and T. Brady, Monocrystalline iron oxide nanocompounds (MION): Physicochemical properties. Magn. Reson. Med. 29, 599 (1993).
24. P. Wunderbaldinger, L. Josephson, and R. Weissleder, Crosslinked iron oxides (CLIO): A new platform for the development of targeted MR contrast agents. Acad. Radiol. 9, 304 (2002).
25. A. Moore, E. Marecos, A. Bogdanov, and R. Weissleder, Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology 214, 568 (2000).
26. C. Oussoren and G. Storm, Lymphatic uptake and biodistribution of liposomes after subcutaneous injection: III. Influence of surface modification with poly(ethyleneglycol). Pharm. Res. 14, 1479 (1997).
27. W. Li, J. Salanitri, S. Tutton, E. E. Dunkle, J. R. Schneider, J. A. Caprini, L. N. Pierchala, P. M. Jacobs, and R. R. Edelman, Lower extremity deep venous thrombosis: Evaluation with ferumoxytol-enhanced MR imaging and dual-contrast mechanism - Preliminary experience. Radiology 242, 873 (2007).
28. F. A. Jaffer, M. Nahrendorf, D. Sosnovik, K. A. Kelly, E. Aikawa, and R. Weissleder, Cellular imaging of inflammation in atherosclerosis using magnetofluorescent nanomaterials. Mol. Imaging 5, 85 (2006).
29. K. A. Kelly, M. Nahrendorf, A. M. Yu, F. Reynolds, and R. Weissleder, In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol. Imaging Biol. 8, 201 (2006).
30. D. Hogemann-Savellano, E. Bos, C. Blondet, F. Sato, T. Abe, L. Josephson, R. Weissleder, J. Gaudet, D. Sgroi, P. J. Peters, and J. P. Basilion, The transferrin receptor: A potential molecular imaging marker for human cancer. Neoplasia 5, 495 (2003).
31. K. A. Kelly, M. Nahrendorf, A. M. Yu, F. Reynolds, and R. Weissleder, In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol. Imaging Biol. 8, 201 (2006).
32. B. A. Moffat, G. R. Reddy, P. McConville, D. E. Hall, T. L. Chenevert, R. R. Kopelman, M. Philbert, R. Weissleder, A. Rehemtulla, and B. D. Ross, A novel Polyacrylamide magnetic nanoparticle contrast agent for molecular imaging using MRI. Mol Imaging 2, 324 (2003).
33. P. M. Winter, A. M. Morawski, S. D. Caruthers, T. D. Harris, J. D. Robertson, T. A. Williams, A. H. Schmieder, G. Hu, J. S. Allen, E. K. Lacy, H. Zhang, S. A. Wickline, and G. M. Lanza, Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108, 2270 (2003).
34. J. M. Perez, L. Josephson, T. O'Loughlin, D. Hogemann, and R. Weissleder, Magnetic relaxation switches capable of sensing molecular interactions. Nat. Biotechnol. 20, 816 (2002).
35. G. A. Tilborg, W. J. Mulder, P. T. Chin, G. Storm, C. P. Reutelingsperger, K. Nicolay, and G. J. Strijkers, Annexin A5 - ~Conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug. Chem. 17, 865 (2006).
36. J. M. Perez, T. O'Loughin, F. J. Simeone, R. Weissleder, and L. Josephson, DNA-based magnetic nanoparticle assembly acts as a magnetic relaxation nanoswitch allowing screening of DNA-cleaving agents. J. Am. Chem. Soc. 124, 2856 (2002).
37. P. Wunderbaldinger, L. Josephson, and R. Weissleder, Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug. Chem. 13, 264 (2002).
38. E. Y. Sun, L. Josephson, K. A. Kelly, and R. Weissleder, Development of nanoparticle libraries for biosensing. Bioconjug. Chem. 17, 109 (2006).
39. P. M. Winter, A. M. Morawski, S. D. Caruthers, R. W. Fuhrhop, H. Zhang, T. A. Williams, J. S. Allen, E. K. Lacy, J. D. Robertson, and G. M. Lanza, Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108, 2270 (2003).
40. M. Brambilla, C. Secco, M. Dominietto, R. Matheoud, G. Sacchetti, and E. Inglese, Performance characteristics obtained for a new 3-dimensional lutetium oxyorthosilicate-based whole-body PET/CT scanner with the National Electrical Manufacturers Association NU 2-2001 standard. J. Nucl. Med. 46, 2083 (2005).
41. P. M. Winter, A. M. Morawski, and S. D. Caruthers, Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation 108, 2270 (2003).
42. C. H. Cunningham, T. Arai, P. C. Yang, M. V. McConnell, J. M. Pauly, and S. M. Conolly, Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Resort. Med. 53, 999 (2005).
43. V. Mani, K. C. Briley-Saebo, V. V. Itskovich, D. D. Samber, and Z. A. Fayad, Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): Sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5 T and 3 T. Magn. Reson. Med. 55, 126 (2006).
44. M. Stuber, W. Gilson, M. Schaer, J. Bulte, and D. Kraitchman, Shedding light on the dark spot with IRON-A method that generates positive contrast in the presence of superparamagnetic nanoparticles. Proc. Intl. Soc. Magn. Reson. Med. 13, 2608 (2005).
45. J. Zhou, J. F. Payen, D. A. Wilson, R. J. Traystman, and P. C. van Zijl, Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat. Med. 9, 1085 (2003).
46. M. Woods, D. E. Woessner, and A. D. Sherry, Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. Chem. Soc. Rev. 35, 500 (2006).
47. S. Aime, C. Carrera, D. Castelli, S. Geninatti, and E. Terreno, Tunable imaging of cells labeled with MRI-PARACEST agents. Angew. Chem. Int. Ed. Engl. 44, 1813 (2005).
48. C. H. Cunningham, T. Arai, P. C. Yang, M. V. McConnell, J. M. Pauly, and S. M. Conolly, Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 53, 999 (2005).
49. V. Mani, K. C. Briley-Saebo, V. V. Itskovich, D. D. Samber, and Z. A. Fayad, Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): Sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5 T and 3 T. Magn. Reson. Med. 55, 126 (2006).
50. C. K. Jones, M. J. Schlosser, P. C. van Zijl, M. G. Pomper, X. Golay, and J. Zhou, Amide proton transfer imaging of human brain tumors at 3 T. Magn. Reson. Med. 56, 585 (2006).
51. M. A. Oghabian, N. Gharehaghaji, S. Amirmohseni, S. Khoei, and M. Guiti, Detection sensitivity of lymph nodes of various sizes using uspio nanoparticles in MRI. J. of Nanomedicine (2009).
52. F. G. Blankenberg, P. D. Katsikis, J. F. Tait, R. E. Davis, L. Naumovski, K. Ohtsuki, S. Kopiwoda, M. J. Abrams, M. Darkes, R. C. Robbins, H. T. Maecker, and H. W. Strauss, In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc. Natl. Acad. Sci. USA 95, 6349 (1998).
53. M. Zhao, D. A. Beauregard, L. Loizou, B. Davletov, and K. M. Brindle, Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat. Med. 7, 1241 (2001).
54. S. Mizukami, K. Kikuchi, T. Higuchi, Y. Urano, T. Mashima, T. Tsuruo, and T. Nagano, Imaging of caspase-3 activation in HeLa cells stimulated with etoposide using a novel fluorescent probe. FEBS Letters 453, 356 (1999).
55. 13lI-labeled peptides as caspase substrates for apoptosis imaging. Journal of Nuclear Medicine 46, 1066 (2005).
56. C. Gladson and D. Cheresh, Glioblastoma expression of vitronectin and the AlphaV-Beta3 Integrin. J. Clin. Invest. 88, 1924 (1991).
57. A. Schmieder, P. Winter, and S. Caruthers, Molecular imaging of angiogenesis in human melanoma xenografts in nude mice by MRI (1.5 T) with αvβ3 targeted nanoparticles. Mol. Imaging 1, 190 (2002).
58. M. V. Backer, V. Patel, B. T. Jehning, and J. M. Backer, Self-assembled "dock and lock" system for linking payloads to targeting proteins. Bioconjug. Chem. 17, 912 (2006).
59. K. Thorstensen and I. Romslo, The transferrin receptor: Its diagnostic value and its potential as therapeutic target. Scand. J. Clin. Lab. Invest. Suppl. 215, 113 (1993).
60. S. D. Konda, M. Aref, M. Brechbiel, and E. C. Wiener, Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: Work in progress. Invest. Radiol. 35, 50 (2000).
61. S. Gohr-Rosenthal, H. Schmitt-Willich, W. Ebert, and J. Conrad, The demonstration of human tumors on nude mice using gadolinium-labelled monoclonal antibodies for magnetic resonance imaging. Invest. Radiol. 28, 789 (1993).
62. D. Artemov, N. Mori, R. Ravi, and Z. M. Bhujwalla, Magnetic resonance molecular imaging of the Her-2/ neu receptor. Cancer Res. 63, 2723 (2003).
63. S. Hacke S. Fischer, M. J. Scott, R. J. Fuhrhop, J. S. Allen, M. McLean, P. Winter, G. A. Sicard, P. J. Gaffney, S. A. Wickline, and G. M. Lanza, Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 104, 1280 (2001).
64. D. Artemov, N. Mori, B. Okollie, and Z. M. Bhujwalla, MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticles. Magn. Reson. Med. 49, 403 (2003).
65. Z. Kachra, E. Beaulieu, N. Delbecchi, F. Mousseau, R. Berthelet, R. Moumdjian, D. Maestro, and R. Beliveau, Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin. Exp. Metastasis 17, 555 (1999).
66. L. Jae-Hyun, Y. Huh, and Y. Wook, Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat. Med. 13, 95 (2007).
67. M. A. Oghabian, M. Jeddi-Tehrani, A. Zolfaghari, F. Shamsipour, S. Khoei, and S. Amanpour, Detectibility of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI. J. Nanosci. Nanotechnol. (2010), in press.
68. S. Kanno, Y. J. Wu, P. C. Lee, S. J. Dodd, M. Williams, B. P. Griffith, and C. Ho, Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation 104, 934 (2001).
69. M. F. Kircher, U. Mahmood, R. S. King, R. Weissleder, and L. Josephson, A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 63, 8122 (2003).
70. D. E. Sosnovik, E. A. Schellenberger, M. Nahrendorf, M. S. Novikov, T. Matsui, G. Dai, F. Reynolds, L. Grazette, A. Rosenzweig, R. Weissleder, and L. Josephson, Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn. Reson. Med. 54, 718 (2005).
71. R. Weissleder, A. S. Lee, B. A. Khaw, T. Shen, and T. J. Brady, Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 182, 381 (1992).
72. J. S. Kerr, S. A. Mousa, and A. M. Slee, Alpha(v)beta(3) integrin in angiogenesis and restenosis. Drug News Perspect. 14, 143 (2001).
73. M. Nahrendorf, F. A. Jaffer, K. A. Kelly, D. E. Sosnovik, E. Aikawa, P. Libby, and R. Weissleder, Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114, 1504 (2006).
74. L. M. Mitsumori, J. L. Ricks, and M. E. Rosenfeld, Development of a lipoprotein based molecular imaging MR contrast agent for the noninvasive detection of early atherosclerotic disease. Int. J. Cardiovasc. Imaging 20, 561 (2004).
75. M. Sirol, V. V. Itskovich, V. Mani, J. Aguinaldo, J. T. Fallon, B. Misselwitz, H. J. Weinmann, V. Fuster, J. F. Toussaint, and Z. A. Fayad, Lipid-rich atherosclerotic plaques detected by gadofluorine enhanced in vivo magnetic resonance imaging. Circulation 109, 2890 (2004).
76. P. M. Winter, S. D. Caruthers, X. Yu, S. K. Song, J. Chen, B. Miller, J. W. Bulte, J. D. Robertson, P. J. Gaffney, S. A. Wickline, and G. M. Lanza, Improved molecular imaging contrast agent for detection of human thrombus. Magn. Reson. Med. 50, 411 (2003).
77. V. Mani, K. C. Briley-Saebo, F. Hyafil, and Z. A. Fayad, Feasibility of in vivo identification of endogenous ferritin with positive contrast MRI in rabbit carotid crush injury using GRASP. Magn. Reson. Med. 56, 1096 (2206).
78. J. W. Chen, S. Querol, A. Bogdanov, and R. Weissleder, Imaging of myeloperoxidase in mice by using novel amplifiable paramagnetic substrates. Radiology 240, 473 (2006).
79. H. W. Kang, L. Josephson, A. Petrovsky, R Weissleder, and A. Bogdanov, Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. Chem. 13, 122 (2002).
80. Y. Z. Wadghiri, E. M. Sigurdsson, M. Sadowski, J. I. Elliott, Y. Li, H. Scholtzova, C. Y. Tang, G. Aguinaldo, M. Pappolla, K. Duff, T. Wisniewski, and D. H. Turnbul, Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn. Reson. Mater. Med. 50, 293 (2003).
81. J. F. Poduslo, G. L. Curran, J. A. Peterson, D. J. McCormick, A. H. Fauq, M. A. Khan, and T. M. Wengenack, Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 43, 6064 (2004).
82. E. M. Sigurdsson, Y. Z. Wadghiri, L. Mosconi, J. A. Blind, E. Knudsen, A. Asuni, H. Scholtzova, W. H. Tsui, Y. Li, M. Sadowski, D. H. Turnbull, M. J. de Leon, and T. Wisniewski, A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol. Aging 29, 836 (2008).
83. L. Larbanoix, C. Burtea, S. Laurent, F. Van Leuven, G. Toubeau, L. Vander Elst, and R. N. Muller, Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer's disease. Neurobiol. Aging doi: 10.1016/j. neurobiolaging.2008.09.021 (2008).
84. J. W. Chen, W. Pham, R. Weissleder, and A. Bogdanov, Human myeloperoxidase: A potential target for molecular MR imaging in atherosclerosis. Magn. Reson. Med. 52, 1021 (2004).
85. C. H. Tung, U. Mahmood, S. Bredow, and R. Weissleder, In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 60, 4953 (2000).